222 related articles for article (PubMed ID: 31736271)
1. Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.
Höflmayer D; Steinhoff A; Hube-Magg C; Kluth M; Simon R; Burandt E; Tsourlakis MC; Minner S; Sauter G; Büscheck F; Wilczak W; Steurer S; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Jacobsen F; Hinsch A; Poos AM; Oswald M; Rippe K; König R; Schroeder C
Mol Oncol; 2020 Jan; 14(1):129-138. PubMed ID: 31736271
[TBL] [Abstract][Full Text] [Related]
2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
[TBL] [Abstract][Full Text] [Related]
4. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
Juhnke M; Heumann A; Chirico V; Höflmayer D; Menz A; Hinsch A; Hube-Magg C; Kluth M; Lang DS; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe R; Thederan I; Schlomm T; Luebke AM
Mol Carcinog; 2017 Sep; 56(9):2135-2145. PubMed ID: 28467610
[TBL] [Abstract][Full Text] [Related]
5. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
7. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
[TBL] [Abstract][Full Text] [Related]
8. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
9. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
Luebke AM; Ricken W; Kluth M; Hube-Magg C; Schroeder C; Büscheck F; Möller K; Dum D; Höflmayer D; Weidemann S; Fraune C; Hinsch A; Wittmer C; Schlomm T; Huland H; Heinzer H; Graefen M; Haese A; Minner S; Simon R; Sauter G; Wilczak W; Meiners J
Int J Cancer; 2020 Jul; 147(2):575-583. PubMed ID: 32150281
[TBL] [Abstract][Full Text] [Related]
10. SNW1 is a prognostic biomarker in prostate cancer.
Höflmayer D; Willich C; Hube-Magg C; Simon R; Lang D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Huland H; Graefen M; Haese A; Heinzer H; Minner S; Büscheck F; Sauter G; Schlomm T; Steurer S; Clauditz TS; Burandt E; Wilczak W; Bernreuther C
Diagn Pathol; 2019 May; 14(1):33. PubMed ID: 31043167
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
[TBL] [Abstract][Full Text] [Related]
13. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
14. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
15. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.
Jacobsen F; Kraft J; Schroeder C; Hube-Magg C; Kluth M; Lang DS; Simon R; Sauter G; Izbicki JR; Clauditz TS; Luebke AM; Hinsch A; Wilczak W; Wittmer C; Büscheck F; Höflmayer D; Minner S; Tsourlakis MC; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Melling N
Neoplasia; 2017 Sep; 19(9):707-715. PubMed ID: 28830008
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
